Driving Innovation in Cancer Care, Redefining Value, Improving Patient Access

The IRA reduces exclusivity for small molecules, affecting drug launch strategies and patient outcomes.

Medicare's share of total costs of care will shift from 80% to 20% starting January 1, 2025.

The IRA also intersects with the EOM for oncology providers, because when patients enter the catastrophic phase, Medicare's Share of Total Costs of Care will shift.

Read the Entire Article